How Otarmeni’s approval fits into the Regeneron Pharmaceuticals (REGN) story

The FDA’s accelerated approval of Otarmeni, the first gene therapy for genetic hearing loss that Regeneron Pharmaceuticals (REGN) plans to provide free to U.S. patients, puts patient access and ESG considerations firmly in focus for investors.

For you as a shareholder or potential buyer, this move sits at the intersection of medicine, brand equity, and long term platform value. It does not point directly to near term revenue, but it does highlight how Regeneron is positioning its gene therapy capabilities and corporate responsibility agenda.

At a share price of $709.10, Regeneron has a 1 day share price return of 1.66% decline and a 30 day share price return of 6.73% decline. Its 1 year total shareholder return of 30.18% sits well above its 3 year total shareholder return of 4.25% decline, pointing to momentum that has cooled in recent months as investors weigh strong Dupixent data, new ESG commitments, insider selling and the latest dividend and buyback updates.

If Otarmeni and Dupixent have you thinking about where future treatments might come from, it can be useful to see what else is emerging across 35 healthcare AI stocks

With shares providing a 1 year total return of 30.18% compared with a softer 3 year record, a value score of 6, and a reported 66% intrinsic discount, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 19% Undervalued

With Regeneron closing at $709.10 against a narrative fair value of $875.31, the current price sits below what this widely followed view implies.

Regeneron's broad and advancing pipeline including recent or upcoming pivotal data in immunology, oncology (notably Lynozyfic and odronnextamab), genetic medicines, and obesity positions the company to benefit from demographic driven increases in demand for advanced therapies and from the rise in personalized and precision medicine, supporting future revenue growth and pipeline driven earnings upside.

Want to see how a maturing pipeline, rising margins and a higher future earnings multiple all feed into that fair value estimate? The full narrative lays out the revenue path, the profitability assumptions, and the earnings power that would need to materialize to bridge the gap between today’s price and that $875.31 figure.

Result: Fair Value of $875.31 (UNDERVALUED)

However, the fair value story still leans on EYLEA facing heavier competition and pricing pressure, as well as on higher R&D spend not always translating into blockbuster launches.

Next Steps

If the mix of opportunity and caution here feels balanced, act while the details are fresh and stress test the data yourself using the 4 key rewards

Looking for more investment ideas?

If Regeneron has sharpened your focus, do not stop here. Broader context from other stocks can help you test your thinking and spot fresh opportunities.

• Compare potential bargains by scanning companies with strong cash flows and quality fundamentals using the 51 high quality undervalued stocks.
• Prioritise resilience by reviewing a curated set of companies that show consistent strength on risk metrics with the 72 resilient stocks with low risk scores.
• Get ahead of the crowd by looking at a screener containing 23 high quality undiscovered gems before they hit more investors' radars.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.